Related Experiment Video
Updated: Apr 12, 2026
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
BBB modulation-driven potentiation of antifungal therapy by melittin in fungal encephalitis
Mingsheng Li1, Jing Ai2, Chengwei Zhang3
1State Key Laboratory of Digital Medical Engineering, Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Sanya 572024, China.
Abstract:
Effective management of fungal encephalitis is constrained by the dual challenge of restricted drug penetration across the blood-brain barrier (BBB) and the inability of conventional antifungal agents to control infection-associated neuroinflammation. In this study, we evaluated melittin (MLT), an amphipathic membrane-active peptide, as a multifunctional therapeutic candidate. In vitro studies confirmed MLT directly inhibited C. albicans growth and attenuated virulence gene expression. Using dual-modal fluorescence and magnetic resonance imaging (MRI), we demonstrated that MLT reversibly and dose-dependently enhances BBB permeability, a critical precondition for central nervous system access. In a murine model of C. albicans-induced fungal encephalitis, MLT outperformed conventional antifungal treatment not only in reducing fungal burden but also in potently suppressing neuroinflammatory responses. Our findings establish MLT as a therapeutic agent that uniquely integrates BBB regulation with pathogen clearance and immunomodulation, offering a coordinated strategy to overcome the core limitations of current antifungal therapies for fungal encephalitis.
Insights
Melittin (MLT) shows promise for treating fungal encephalitis by enhancing blood-brain barrier (BBB) permeability and reducing inflammation. This peptide offers a novel approach to combatting brain infections more effectively than traditional antifungal drugs.
Area of Science:
- Neuroscience
- Infectious Diseases
- Pharmacology
Background:
- Fungal encephalitis management is limited by poor drug delivery across the blood-brain barrier (BBB) and neuroinflammation.
- Conventional antifungal therapies struggle to address both the pathogen and the host inflammatory response in the central nervous system.
Purpose of the Study:
- To evaluate melittin (MLT), a membrane-active peptide, as a multifunctional therapeutic for fungal encephalitis.
- To assess MLT's ability to inhibit fungal growth, modulate BBB permeability, and reduce neuroinflammation.
Main Methods:
- In vitro assessment of MLT's antifungal activity and virulence gene expression inhibition against Candida albicans.
- In vivo evaluation of MLT's effect on BBB permeability using dual-modal imaging (fluorescence and MRI) in a murine model.
- Comparative analysis of MLT and conventional antifungal treatments in a murine model of fungal encephalitis, assessing fungal burden and neuroinflammation.
Main Results:
- MLT demonstrated direct inhibition of Candida albicans growth and attenuated virulence gene expression in vitro.
- MLT was shown to reversibly and dose-dependently enhance BBB permeability, facilitating CNS drug access.
- In a murine model, MLT significantly reduced fungal burden and suppressed neuroinflammatory responses, outperforming conventional antifungal treatments.
Conclusions:
- Melittin (MLT) is a multifunctional therapeutic candidate for fungal encephalitis, uniquely combining BBB modulation with direct antifungal and immunomodulatory effects.
- MLT offers a coordinated strategy to overcome the limitations of current antifungal therapies by improving CNS penetration and managing neuroinflammation.
Related Concept Videos
01:15Antifungal Agents
01:15Anthelminthic Agents